A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely ...

Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the ...

Medicare Part D prescription drug plans may offer coverage for Airsupra. However, a plan would need to include the drug in its formulary. Learn more.

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2024 ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

The pharma giant's chief exec Emma Walmsley (pictured) said European nations faced 'tough choices' on investment'.